4.5 Article

Structural and clinical characterization of CYP11B2 inhibition by dexfadrostat phosphate

Related references

Note: Only part of the references are listed.
Article Peripheral Vascular Disease

Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers

Mason W. Freeman et al.

Summary: This study evaluated the safety, pharmacokinetics, and pharmacodynamics of Baxdrostat in healthy volunteers. The results demonstrated that Baxdrostat can dose-dependently reduce plasma aldosterone levels, while having no significant impact on cortisol levels. Furthermore, the half-life of Baxdrostat supports once-daily dosing.

HYPERTENSION RESEARCH (2023)

Article Cardiac & Cardiovascular Systems

HIGHLY EFFECTIVE BLOOD PRESSURE LOWERING WITH MLS-101, A NEW ALDOSTERONE SYNTHASE INHIBITOR, IN INDIVIDUALS WITH OBESITY AND RAAS DYSREGULATION

David Rodman et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Article Medicine, General & Internal

Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension The Target-HTN Randomized Clinical Trial

Luke J. Laffin et al.

Summary: Excess aldosterone production is a contributor to hypertension, and therapies that reduce aldosterone synthesis may lower blood pressure. This study compares the safety and efficacy of an aldosterone synthase inhibitor, lorundrostat, with placebo, and identifies dose-dependent outcomes to inform future trials.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Article Biochemical Research Methods

Parallel targeted and non-targeted quantitative analysis of steroids in human serum and peritoneal fluid by liquid chromatography high-resolution mass spectrometry

Thomas Andrieu et al.

Summary: We developed a liquid chromatography high-resolution mass spectrometry method for the absolute quantification of 51 steroids in human serum and peritoneal fluid, allowing accurate and precise analysis of classical and non-classical steroids. The approach enables post hoc analysis of clinical samples for any steroid once a standard becomes available. It has been demonstrated to evaluate differences in steroid content between peripheral serum and peritoneal fluid across menstrual cycle phases and the effect of the synthetic gestagen dienogest on the steroid metabolome.

ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2022)

Article Endocrinology & Metabolism

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease

Monica Gadelha et al.

Summary: This study aimed to evaluate the safety and effectiveness of osilodrostat in treating Cushing disease. The results showed that osilodrostat rapidly normalized cortisol excretion in most patients and maintained this effect throughout the study.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Cell Biology

Origin of circulating 18-oxocortisol in the normal human adrenal

Celso E. Gomez-Sanchez et al.

Summary: 18-Oxocortisol is the product of the metabolism of 11-deoxycortisol by the mitochondrial enzyme aldosterone synthase (CYP11B2). The study found that CYP11B2 and the 17 alpha-hydroxylase enzyme (CYP17A1) required for the synthesis of 11-deoxycortisol are co-expressed in different regions of the human adrenal gland. Additionally, it was discovered that cells expressing only CYP17A1 may provide a paracrine substrate for the synthesis of 18-oxocortisol.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2022)

Article Biochemistry & Molecular Biology

Human cytochrome P450 11B2 produces aldosterone by a processive mechanism due to the lactol form of the intermediate 18-hydroxycorticosterone

Michael J. Reddish et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2019)

Article Chemistry, Medicinal

Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) Inhibitors

Steven M. Sparks et al.

ACS MEDICINAL CHEMISTRY LETTERS (2019)

Article Biochemistry & Molecular Biology

Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design

Simone Brixius-Anderko et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2019)

Article Biochemistry & Molecular Biology

A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors

Anastasios Mangelis et al.

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)

Article Peripheral Vascular Disease

LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase

Joanne Sloan-Lancaster et al.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2017)

Article Endocrinology & Metabolism

Structural Insights into Aldosterone Synthase Substrate Specificity and Targeted Inhibition

Natallia Strushkevich et al.

MOLECULAR ENDOCRINOLOGY (2013)

Article Chemistry, Medicinal

Novel Aromatase Inhibitors by Structure-Guided Design

Debashis Ghosh et al.

JOURNAL OF MEDICINAL CHEMISTRY (2012)

Review Cell Biology

Acute and chronic regulation of aldosterone production

Namita G. Hattangady et al.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)

Review Endocrinology & Metabolism

The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders

Walter L. Miller et al.

ENDOCRINE REVIEWS (2011)

Article Biochemistry & Molecular Biology

The Protein Data Bank

HM Berman et al.

NUCLEIC ACIDS RESEARCH (2000)